Myxoid liposarcoma

Myxoid liposarcoma is a rare malignant tumor that arises from mature adipose tissue and is characterized by myxoid or mucinous degradation. This type of liposarcoma usually occurs in soft tissues, predominantly in the extremities and trunk, but can also develop in other parts of the body. Myxoid liposarcoma is often diagnosed in adults aged 30-60 years, has a high potential for local invasion and metastasis. Clinical and morphological features of this tumor include the presence of extensive myxoid stroma, as well as various cellular elements, which makes it morphologically diverse and difficult to diagnose.

History of the disease and interesting historical facts

Myxoid liposarcoma was first described in the literature at the beginning of the 20th century, when active studies of soft tissue tumors began. Initially, this disease was studied in the context of a common liposarcoma, but over time, the isolation of the myxoid form became an independent topic for study. An interesting fact is that myxoid liposarcoma was the first of all liposarcoma forms for which a specific chromosomal aberration was determined, namely, translocation 12;16, discovered in 1991, which gave a new impetus to molecular diagnostics and therapy of this pathology.

Epidemiology

Epidemiological data show that myxoid liposarcoma accounts for approximately 15-20% of all liposarcoma cases. According to studies, the incidence of this tumor varies from 0.5 to 2 cases per million population per year. Men suffer from myxoid liposarcoma slightly more often than women, and the age of most patients ranges from 40 to 60 years. It is important to note that there is a trend towards an increase in the number of myxoid liposarcoma diagnoses due to improvements in imaging and molecular diagnostics.

Genetic predisposition to this disease

At the molecular genetic level, myxoid liposarcoma is associated with certain genetic changes. The main mechanical basis of this tumor is chromosomal transformations, in particular, translocation 12;16 (q13;p11), which leads to activation of the FUS gene and the formation of a new fusion gene FUS-DDIT3. Other mutations affecting genes responsible for cell cycle regulation and controlling apoptosis have also been identified. The study of genetic predispositions associated with the development of myxoid liposarcoma allows not only to deepen the understanding of the mechanisms of its pathogenesis, but also to develop new targeted approaches to treatment.

Risk factors for the development of this disease

There are a number of factors that contribute to the development of myxoid liposarcoma, among which are:

• Genetic mutations associated with gene translocation as explained above.
• Long-term exposure to ionizing radiation, such as during treatment of other types of cancer.
• Contact with certain chemical compounds, including chemotherapy drugs.
• Chronic inflammatory processes that can provoke changes in tissues.
• Age and gender: Men aged 40-60 years are the main risk group.

Diagnosis of this disease

Diagnosis of myxoid liposarcoma is based on a combination of clinical, laboratory and radiological studies. The main symptoms may vary depending on the location of the tumor, but the most common are:

• The presence of a painless swelling in the limb or trunk.
• Hyperthermia or swelling at the site of formation.
• Symptoms of local pressure on adjacent structures.

Laboratory tests such as blood tests and biopsy are preferably performed for morphological verification. Radiological examinations (ultrasound, CT, MRI) play a key role in determining the size and extent of the tumor, as well as in planning surgical intervention. Differential diagnosis should be made with other local malignancies, such as other types of liposarcomas or fibrosarcomas, as well as benign neoplasms.

Treatment

Treatment of myxoid liposarcoma involves a comprehensive approach and depends on the stage of the disease. The main method is surgical intervention aimed at complete removal of the tumor without residual processes. When the tumor is localized, radical resection is the most effective treatment. In the presence of metastases, adjuvant and neoadjuvant chemotherapy may be indicated, aimed at reducing the tumor size before surgery or suppressing residual cells after removal. Modern studies are also considering the possibility of targeted therapy aimed at specific molecules associated with the pathogenesis of the disease.

List of medications used to treat this disease

The main drugs used to treat myxoid liposarcoma include:

• Doxorubicin is a chemotherapeutic drug used in the treatment of sarcomas.
• Ifosfamide is used for systemic treatment of metastatic forms.
• Mifepristone - used in some clinical trials for castration therapy.
• Toxoracin is similarly used in therapeutic regimens for liposarcomas.
• Targeted agents such as apoptosis inhibitors are under investigation.

Disease monitoring

Patient monitoring after treatment for myxoid liposarcoma consists of regular follow-up examinations, including clinical examinations and radiological studies. The prognosis depends on the stage of the disease at diagnosis. With early diagnosis and successful tumor resection, survival can reach 75-80%, while in the presence of metastases, 5-year survival is significantly reduced. Complications may include recurrence of the disease and damage to surrounding tissues during treatment, so careful follow-up is essential.

Age-related features of the disease

Myxoid liposarcoma most often occurs in people aged 40-60 years, but cases can also occur in young people. It is extremely rare in children and adolescents. In elderly patients, the disease may proceed with an unclear clinical picture, which complicates diagnosis in the early stages. In the age group of 30-40 years, the tumor may manifest itself more aggressively than in adulthood, which requires a careful approach to treatment.

Questions and Answers

• What is the main cause of myxoid liposarcoma? The main cause of myxoid liposarcoma is genetic mutations, especially those associated with the chromosomal translocation 12;16.
• What diagnostic methods are most effective in detecting myxoid liposarcoma? The most effective diagnostic methods are a combination of imaging methods (CT, MRI) and morphological examination of the tumor biopsy.
• What is the survival rate for patients with myxoid liposarcoma? The survival rate of patients with myxoid liposarcoma in the early stages of the disease can reach 75-80%, but in the presence of metastases it is significantly reduced.
• What is the standard treatment for myxoid liposarcoma? Standard treatment is surgery to completely remove the tumor; depending on the stage, chemotherapy and targeted therapy may be prescribed.
• Are there any age-related features in the course of the disease? Yes, myxoid liposarcoma is more common in people aged 40-60 years, but may be more aggressive in younger people.